Literature DB >> 15488864

IL-6 and the acute phase response in murine atherosclerosis.

Li Song1, Christian Schindler.   

Abstract

Numerous studies have implicated C-reactive protein (CRP) and the acute phase response (APR) in the development of atherosclerotic heart disease. Interleukin (IL)-6, which regulates both CRP expression and the APR, has also been identified as a risk factor for heart disease. To more directly evaluate the role of IL-6 in the development of atherosclerosis, IL-6 knockout mice were crossed with atherosclerosis prone LDL receptor (LDL-R) knockout mice. Lesion development was evaluated on Chow, Western type and Paigen diets. As anticipated, the Paigen diet stimulated the expression of APR genes in LDL-R[-/-] mice, but not IL-6[-/-]/LDL-R[-/-] mice. Despite this difference in acute phase response, only modest and statistically not significant differences were noted in the development of atherosclerotic lesions in LDL-R[-/-] and IL-6[-/-]/LDL-R[-/-] mice. These observations suggest that IL-6 and the acute phase response may not play as significant role in atherogenesis as other studies have indicated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15488864     DOI: 10.1016/j.atherosclerosis.2004.06.018

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  26 in total

1.  Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the proinflammatory response.

Authors:  Eric Frisdal; Philippe Lesnik; Maryline Olivier; Paul Robillard; M John Chapman; Thierry Huby; Maryse Guerin; Wilfried Le Goff
Journal:  J Biol Chem       Date:  2011-07-08       Impact factor: 5.157

2.  Up-regulation of endothelial monocyte chemoattractant protein-1 by coplanar PCB77 is caveolin-1-dependent.

Authors:  Zuzana Majkova; Eric Smart; Michal Toborek; Bernhard Hennig
Journal:  Toxicol Appl Pharmacol       Date:  2009-03-02       Impact factor: 4.219

3.  Peripheral Th17/Treg imbalance in patients with atherosclerotic cerebral infarction.

Authors:  Qing Li; Yiping Wang; Feng Yu; Yuan Min Wang; Cuiping Zhang; Chaojie Hu; Zhiwei Wu; Xiucai Xu; Shilian Hu
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

4.  Deletion of the murine scavenger receptor CD68.

Authors:  Li Song; Carolyn Lee; Christian Schindler
Journal:  J Lipid Res       Date:  2011-05-13       Impact factor: 5.922

Review 5.  Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease.

Authors:  José J Fuster; Noriyuki Ouchi; Noyan Gokce; Kenneth Walsh
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

Review 6.  Interleukin-17 contributes to cardiovascular diseases.

Authors:  Hua-Sheng Ding; Jun Yang; Jian Yang; Jia-Wang Ding; Ping Chen; Ping Zhu
Journal:  Mol Biol Rep       Date:  2012-02-14       Impact factor: 2.316

7.  IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice.

Authors:  Shuang Chen; Kenichi Shimada; Wenxuan Zhang; Ganghua Huang; Timothy R Crother; Moshe Arditi
Journal:  J Immunol       Date:  2010-10-08       Impact factor: 5.422

8.  Induction of IL-6 expression by mechanical stress in the trabecular meshwork.

Authors:  Paloma B Liton; Coralia Luna; Marc Bodman; Anna Hong; David L Epstein; Pedro Gonzalez
Journal:  Biochem Biophys Res Commun       Date:  2005-10-07       Impact factor: 3.575

Review 9.  Cytokine network and T cell immunity in atherosclerosis.

Authors:  Hafid Ait-Oufella; Soraya Taleb; Ziad Mallat; Alain Tedgui
Journal:  Semin Immunopathol       Date:  2009-04-02       Impact factor: 9.623

10.  Aortic cholesterol accumulation correlates with systemic inflammation but not hepatic and gonadal adipose tissue inflammation in low-density lipoprotein receptor null mice.

Authors:  Shu Wang; Bradley Miller; Nirupa R Matthan; Zeynep Goktas; Dayong Wu; Debra B Reed; Xiangling Yin; Paula Grammas; Naima Moustaid-Moussa; Chwan-Li Shen; Alice H Lichtenstein
Journal:  Nutr Res       Date:  2013-12       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.